INIS
glucose
100%
metabolism
100%
sodium
100%
substrates
100%
insulin
100%
oxidation
100%
levels
57%
muscles
57%
glycogen
57%
mitochondria
42%
fats
42%
capacity
42%
lipids
42%
liver
28%
patients
28%
comparative evaluations
28%
auc
28%
diseases
14%
biopsy
14%
risks
14%
blood
14%
diabetes mellitus
14%
design
14%
fatty acids
14%
energy
14%
kidneys
14%
weight
14%
hypothesis
14%
balances
14%
heart failure
14%
plasma
14%
excretion
14%
carbohydrates
14%
energy losses
14%
Keyphrases
Randomized Double-blind
100%
Insulin Resistance
100%
Pre-diabetes (pre-DM)
100%
Substrate Metabolism
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
100%
Dapagliflozin
100%
Placebo
45%
Glycogen Content
27%
Lipid Content
27%
Mitochondrial Oxidative Capacity
27%
Skeletal muscle
18%
Fat Oxidation
18%
Hepatic Lipid
18%
Hepatic Glycogen
18%
Metabolic Adaptation
18%
Randomized Placebo-controlled Trial
9%
Heart Failure
9%
Without Diabetes
9%
AIMS™
9%
Energy Loss
9%
Chronic Kidney Disease
9%
Muscle Biopsy
9%
Insulin Level
9%
Crossover Design
9%
Whole-body
9%
Muscle Glycogen
9%
Substrate Oxidation
9%
Plasma Glucose
9%
Free Fatty Acids
9%
Carbohydrate Oxidation
9%
Metabolic Effects
9%
Human muscle
9%
Caloric Restriction
9%
Type 2 Diabetes Mellitus Patients
9%
Negative Energy Balance
9%
Fat Balance
9%
Glucosuria
9%
Urinary Glucose Excretion
9%
Weight Neutral
9%
Hydroxybutyrate
9%
Medicine and Dentistry
Sodium Glucose Cotransporter 2 Inhibitor
100%
Dapagliflozin
100%
Placebo
54%
Glucosuria
18%
Skeletal Muscle
18%
Fatty Acid
9%
Urinary System
9%
Maturity Onset Diabetes of the Young
9%
Body Mass Index
9%
Diabetes
9%
Muscle Biopsy
9%
Ex Vivo
9%
Chronic Kidney Disease
9%
Congestive Heart Failure
9%
Caloric Restriction
9%
Hydroxybutyric Acid
9%
Pharmacology, Toxicology and Pharmaceutical Science
Dapagliflozin
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Placebo
54%
Glucosuria
18%
Fatty Acid
9%
Congestive Heart Failure
9%
Chronic Kidney Failure
9%
Hydroxybutyric Acid
9%
Non Insulin Dependent Diabetes Mellitus
9%
Agricultural and Biological Sciences
Placebo
100%
Cotransporter
100%
Skeletal Muscle
33%
Body Mass Index
16%
Urinary System
16%
Ex Vivo
16%
Blood Plasma
16%
Fatty Acids
16%